HER2 fragmentation and breast cancer stratification.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20682714.
- Also identified by DOI 10.1158/1078-0432.CCR-10-1501.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Peptide Fragments
- Erb-b2 Receptor Tyrosine Kinases